Beyond the SMO: A New Model Is Emerging in Clinical Research
The traditional site management organization (SMO) model, providing operational support services like staffing, recruitment coordination, and regulatory documentation across a network of affiliated sites, has served the clinical trial industry for decades. But a meaningful evolution is now underway, with industry observers increasingly describing the emergence of the Site Research Organization (SRO), a more centrally administered, technology-enabled model that layers substantially more research capability directly onto the traditional site management function. Understanding this evolution matters for Seven Health and 7 Consult's own approach to building embedded research infrastructure, since it describes precisely the direction the most competitive site networks are moving.
What Separates a Site Research Organization From a Traditional SMO
A traditional SMO's core value proposition centers on operational support and consistency: helping a network of sites manage staffing, regulatory paperwork, and day-to-day study coordination more efficiently than each site could manage independently. A Site Research Organization builds on that foundation but extends meaningfully further, typically incorporating:
- Integrated data management and biostatistics capability, rather than relying entirely on the sponsor's or CRO's separate data management function
- Centralized regulatory and quality infrastructure, allowing the organization to maintain consistent, auditable quality systems across every affiliated site rather than each site managing quality independently
- Direct patient access and identification technology, often built around EHR integration and population health data, rather than depending purely on individual site-level recruitment effort
- A more direct, less layered relationship with sponsors, positioning the organization as a genuine research partner capable of speaking to protocol design and feasibility strategy, not simply executing a pre-defined operational scope
Why This Evolution Is Happening Now
This shift is being driven by the same patient identification and recruitment bottleneck that has become increasingly central to clinical trial success. With over half of drugs currently in active development targeting rare, orphan, or oncology indications, where eligible patient populations are inherently narrow and geographically dispersed, the traditional model of a sponsor working through a loosely affiliated patchwork of independent sites and a separate CRO has become a genuine constraint on program timelines. Site Research Organizations are emerging specifically to close that gap, offering sponsors a more direct, more integrated path from program strategy through to actual patient enrollment.
Investment activity reflects this shift clearly, with more than fifteen distinct transactions in the broader patient access and site network space occurring within recent 24-month periods, as investors and larger CROs recognize the strategic value of organizations that can offer this more integrated capability rather than pure operational site support alone.
The Embedded Research Model as a Natural SRO Foundation
This is where Seven Health and 7 Consult's own positioning becomes directly relevant. An embedded research network, built inside an existing care delivery system with a large, characterized patient population and an established EHR infrastructure, has a genuinely natural foundation for evolving toward the Site Research Organization model, arguably a stronger starting point than a traditional SMO that has grown primarily through acquiring previously independent, operationally disparate sites. An embedded network already has the patient population data, the existing clinical infrastructure, and, critically, the community trust relationship that a rapidly assembled acquisition-based platform often has to rebuild from scratch across each newly acquired site.
What Sponsors Actually Want From This Evolved Model
Sponsors and CROs evaluating a Site Research Organization versus a traditional SMO or independent site relationship are typically looking for evidence of a few specific, elevated capabilities beyond standard operational site support:
- Direct feasibility data generation, meaning the organization can produce verified, population-level enrollment projections rather than relying on individual site estimates that vary widely in accuracy
- Cross-site data consistency, since a centrally administered data management and quality infrastructure reduces the variability sponsors otherwise have to manage across a loosely affiliated site network
- Protocol design input, where sponsors increasingly value a research partner capable of providing genuine feedback on protocol feasibility and patient burden before a study is finalized, rather than simply receiving a completed protocol and executing it
- Technology and data governance maturity, particularly around the kind of AI-assisted patient identification and structured data infrastructure described in Seven Health's broader work on clinical trial technology readiness
Building Toward the SRO Model: A Practical Path
For an embedded research network or independent site group considering how to evolve toward this more integrated model, the practical build-out sequence typically starts with strengthening the foundational elements before layering on more advanced capability: establishing consistent, centrally managed quality and regulatory infrastructure across every affiliated location, investing in the data governance and EHR integration work needed to support genuine population-level feasibility data, and building the internal expertise, whether through hiring or partnership, to engage credibly with sponsors on protocol design and feasibility strategy rather than purely operational execution.
A Practical Roadmap Toward the SRO Model
Networks evaluating whether and how to pursue this evolution can work through a sequenced set of priorities: start with a honest assessment of current quality and regulatory infrastructure consistency across every affiliated site, since centralization here is the foundation everything else builds on; invest in the data governance and EHR integration work needed to produce genuine, verifiable population-level feasibility data rather than site-by-site estimates; build or acquire the internal expertise needed to engage credibly with sponsors on protocol feasibility and design input, which is a materially different conversation than purely operational site execution; and pursue this evolution incrementally, proving the model with a smaller set of pilot studies before positioning the network broadly as a full Site Research Organization capability to the sponsor and CRO market.
Frequently Asked Questions on the SRO Evolution
Is becoming a Site Research Organization only realistic for large, well-funded networks?
Not necessarily. While scale helps, the core differentiators, data governance maturity, centralized quality infrastructure, and genuine population-level feasibility capability, are achievable for mid-size embedded networks with strong underlying patient population data, even without the scale of a large, multi-state SMO platform.
How is a Site Research Organization different from simply being a larger site network?
Scale alone doesn't define an SRO. The distinguishing factor is the depth of integrated research capability, particularly data management, quality infrastructure, and protocol-level engagement with sponsors, layered on top of the traditional operational site support function.
Does the SRO model compete with or complement traditional CRO relationships?
Generally complements, since most SROs still work within the broader sponsor-CRO-site structure rather than replacing CRO functions entirely. The distinction is that an SRO brings more integrated research capability to that relationship than a traditional site or SMO would on its own.
Conclusion
The evolution from traditional site management organizations toward more integrated Site Research Organizations reflects a genuine structural response to the patient identification and recruitment complexity defining modern clinical trials, particularly in rare disease and oncology. Seven Health and 7 Consult believe embedded research networks, built on an existing trusted care relationship and a genuine patient population, are uniquely well positioned to lead this evolution rather than simply following the acquisition-driven consolidation happening elsewhere in the site management market.
